PURPOSE: In this manuscript, the safety and efficacy of adjuvant interferon alfa 2b treatment of uveal melanoma is described. PATIENTS AND METHODS: A total of 39 patients (23 male and 16 female, mean age 56.5 years, range 35-78 years) with uveal melanoma were treated with interferon alfa 2b, 3 million units three times a week subcutaneously for 1 year after therapy of the primary tumor. In all patients age, gender, primary melanoma data, therapeutic interventions, treatment side effects and outcome were documented. RESULTS: Of the 39 patients, 31 (80%) finished the treatment as scheduled after 1 year. In 18 patients (46%) the initial dose had to be reduced due to leucopenia, thrombopenia, cardiac symptoms, elevated of liver function or vertigo (WHO grade I-III). In eight patients, therapy had to be withdrawn because of serious side effects (five patients) and the appearance of metastases (three patients). Neither a univariate approach nor a multivariate approach could show a protective effect of interferon treatment on survival. CONCLUSIONS: Adjuvant treatment of uveal melanoma with interferon alfa should be abandoned until the question of dose and administration for cutaneous melanoma is solved.
PURPOSE: In this manuscript, the safety and efficacy of adjuvant interferon alfa 2b treatment of uveal melanoma is described. PATIENTS AND METHODS: A total of 39 patients (23 male and 16 female, mean age 56.5 years, range 35-78 years) with uveal melanoma were treated with interferon alfa 2b, 3 million units three times a week subcutaneously for 1 year after therapy of the primary tumor. In all patients age, gender, primary melanoma data, therapeutic interventions, treatment side effects and outcome were documented. RESULTS: Of the 39 patients, 31 (80%) finished the treatment as scheduled after 1 year. In 18 patients (46%) the initial dose had to be reduced due to leucopenia, thrombopenia, cardiac symptoms, elevated of liver function or vertigo (WHO grade I-III). In eight patients, therapy had to be withdrawn because of serious side effects (five patients) and the appearance of metastases (three patients). Neither a univariate approach nor a multivariate approach could show a protective effect of interferon treatment on survival. CONCLUSIONS: Adjuvant treatment of uveal melanoma with interferon alfa should be abandoned until the question of dose and administration for cutaneous melanoma is solved.
Authors: I W McLean; D Berd; M J Mastrangelo; J A Shields; F H Davidorf; M Grever; T A Makley; J W Gamel Journal: Am J Ophthalmol Date: 1990-11-15 Impact factor: 5.258
Authors: J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: G Langmann; W Wackernagel; G Stücklschweiger; K Feichtinger; G Papaefthymiou; J Faulborn Journal: Ophthalmologe Date: 2004-11 Impact factor: 1.059
Authors: Shaheer Khan; Jose Lutzky; Alexander N Shoushtari; Joanne Jeter; Brian Marr; Thomas E Olencki; Colleen M Cebulla; Mohamed Abdel-Rahman; J William Harbour; Naomi Sender; Alexandra Nesson; Shahnaz Singh-Kandah; Susana Hernandez; Jeanelle King; Manpreet S Katari; Lyssa Dimapanat; Stephanie Izard; Grazia Ambrosini; Oliver Surriga; Alex J Rai; Codruta Chiuzan; Gary K Schwartz; Richard D Carvajal Journal: Front Oncol Date: 2022-08-29 Impact factor: 5.738